Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel of chemoresistant bladder cancer cell lines

Abstract

Aim: Urinary bladder cancer (UBC) often develops chemoresistance, reducing treatment effectiveness. This study aimed to investigate diverse molecular mechanisms underlying acquired resistance by establishing and characterizing a comprehensive panel of UBC cell lines resistant to common chemotherapeutics.

Methods: Fifteen UBC cell lines were examined: three parental lines (RT-112, TCC-SUP, UMUC-3) and twelve derived sublines adapted to cisplatin, vinblastine, or gemcitabine. Drug sensitivity was assessed using the SRB assay. Resistance mechanisms were explored via quantitative real-time PCR (targeting genes including ABCB1, dCK, hENT1, ECHDC1, TUBB3), Western blotting (assessing proteins such as p21, Cyclin B, and Mcl-1), and biochemical assessment of glutathione levels and redox state.

Results: The adapted sublines exhibited distinct resistance profiles and cross-resistance patterns. Gene expression and protein analyses revealed drug- and lineage-specific alterations, involving factors such as p21, Cyclin B, and Mcl-1. Changes in glutathione metabolism were also associated with resistance. Notably, no single, universal mechanism accounted for resistance across the entire panel.

Conclusion: UBC cells develop diverse, context-dependent adaptive strategies to resist cisplatin, vinblastine, and gemcitabine. These findings highlight the complexity of chemoresistance mechanisms. The characterized cell line panel represents a valuable resource for future studies aimed at understanding and overcoming drug resistance in bladder cancer, suggesting that personalized therapeutic approaches may be necessary.

Keywords

Transitional cell carcinoma / drug resistance / in vitro urinary bladder cancer model

References

[1] Jubber I,Bukavina L.Epidemiology of bladder cancer in 2023: a systematic review of risk factors.Eur Urol2023;84:176-90

[2] Vermeulen R,Dagnino S.A prospective study of smoking-related white blood cell DNA methylation markers and risk of bladder cancer.Eur J Epidemiol2024;39:393-407 PMCID:PMC11101379

[3] Saginala K,Aluru JS,Padala SA.Epidemiology of bladder cancer.Med Sci2020;8:15 PMCID:PMC7151633

[4] Massari F,Ciccarese C.Emerging concepts on drug resistance in bladder cancer: implications for future strategies.Crit Rev Oncol Hematol2015;96:81-90

[5] Yue P,Zhao Y.Focus on the molecular mechanisms of cisplatin resistance based on multi-omics approaches.Mol Omics2023;19:297-307

[6] Mari A,Abufaraj M,Kimura S.Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.Transl Androl Urol2017;6:1081-9 PMCID:PMC5760393

[7] Khan SU,Aisha S.Unveiling the mechanisms and challenges of cancer drug resistance.Cell Commun Signal2024;22:109 PMCID:PMC10860306

[8] Earl J,Carrillo-de-Santa-Pau E.The UBC-40 urothelial bladder cancer cell line index: a genomic resource for functional studies.BMC Genomics2015;16:403 PMCID:PMC4470036

[9] Yang W,Greninger P.Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.Nucleic Acids Res2013;41:D955-61 PMCID:PMC3531057

[10] Michaelis M,Cinatl J.Drug-adapted cancer cell lines as preclinical models of acquired resistance.Cancer Drug Resist2019;2:447-56 PMCID:PMC8992517

[11] Skehan P,Scudiero D.New colorimetric cytotoxicity assay for anticancer-drug screening.J Natl Cancer Inst1990;82:1107-12

[12] Chomczynski P.Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.Anal Biochem1987;162:156-9

[13] Pan H,Beshiri ML.Gambogic acid inhibits thioredoxin activity and induces ROS-mediated cell death in castration-resistant prostate cancer.Oncotarget2017;8:77181-94 PMCID:PMC5652772

[14] Genovese I,Assaraf YG,Colotti G.Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.Drug Resist Updat2017;32:23-46

[15] Villa E.ASS1igning purine dependency to cancer.Nat Cancer2020;1:862-3

[16] Nicholson LJ,Hiller L.Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.Int J Cancer2009;125:1454-63

[17] Yeon A,Kim M.Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.Theranostics2018;8:4520-34 PMCID:PMC6134931

[18] Petruzzelli R.Activity and trafficking of copper-transporting ATPases in tumor development and defense against platinum-based drugs.Cells2019;8:1080 PMCID:PMC6769697

[19] Saiki Y,Fujimura H.DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.Biochem Biophys Res Commun2012;421:98-104

[20] Asai S,Sawada Y.Silencing of ECHDC1 inhibits growth of gemcitabine-resistant bladder cancer cells.Oncol Lett2018;15:522-7 PMCID:PMC5769416

[21] Xi Y,Li T,Liu MF.hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.Cancer Lett2020;479:112-22

[22] Saga Y,Yachiku S,Tokumitsu M.Reversal of acquired cisplatin resistance by modulation of metallothionein in transplanted murine tumors.Int J Urol2004;11:407-15

[23] Yoo HC.Amino acid metabolism in cancer drug resistance.Cells2022;11:140 PMCID:PMC8750102

[24] Kavallaris M,Norris MD.Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.Cancer Res2001;61:5803-9

[25] Liu Y.Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Mol Cancer Ther2015;14:174-82 PMCID:PMC4297264

[26] Zeng SX,Ma AH.The phosphatidylinositol 3-kinase pathway as a potential therapeutic target in bladder cancer.Clin Cancer Res2017;23:6580-91 PMCID:PMC5668181

[27] Borcoman E,Richer W.Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.Oncoimmunology2019;8:e1581556 PMCID:PMC6492984

[28] Kimura Y,Matsuo M.Mechanism of multidrug recognition by MDR1/ABCB1.Cancer Sci2007;98:1303-10 PMCID:PMC11159003

[29] Liu R,Liu G.PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.Cell Death Dis2020;11:797 PMCID:PMC7515865

[30] Shah MA.Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.Clin Cancer Res2001;7:2168-81

[31] Wei J,Long M.p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell.BMC Cancer2010;10:632 PMCID:PMC2995802

[32] Martinez A,Arpi O.Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: rational for its testing in clinical trials.J Clin Oncol2015;33:369

[33] Galluzzi L,Vitale I.Molecular mechanisms of cisplatin resistance.Oncogene2012;31:1869-83

[34] Chen HH.Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy.Met Based Drugs2010;2010:1-7 PMCID:PMC2946579

[35] Shi Y,Wang T.Targeting KRAS: from metabolic regulation to cancer treatment.Mol Cancer2025;24:9 PMCID:PMC11724471

[36] Rapozzi V,Di Giorgio E.KRAS and NRF2 drive metabolic reprogramming in pancreatic cancer cells: the influence of oxidative and nitrosatice stress.Front Cell Dev Biol2025;13:1547582 PMCID:PMC12187747

[37] Mukhopadhyay S,McCormick F.The metabolic landscape of RAS-driven cancers from biology to therapy.Nat Cancer2021;2:271-83 PMCID:PMC8045781

[38] Mezencev R,Wagner GT.Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes.Cancer Gene Ther2016;23:446-53 PMCID:PMC5159445

[39] Arnesano F.“Platinum on the road”: interactions of antitumoral cisplatin with proteins.Pure Appl Chem2008;80:2715-25

[40] Zheng J,Li L.Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review.Front Chem2022;10:860985 PMCID:PMC9046545

[41] Lau DK,Weickhardt A.Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy.Cancer Drug Resist2019;2:568-79 PMCID:PMC8992533

[42] Li P,Lu W.Targeting FGFR3 signaling and drug repurposing for the treatment of SLC26A2-related chondrodysplasia in mouse model.J Orthop Translat2024;44:88-101 PMCID:PMC10818158

[43] Attaoua C,Abdel Jaoued A.Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids.Fundam Clin Pharmacol2015;29:62-71

[44] Pettitt GA,Khan Z.Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro.J Pathol2023;259:220-32 PMCID:PMC10107504

[45] Le TVT,Ryu CJ,Park HJ.Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3.Arch Pharm Res2010;33:1127-32

[46] Nickerson ML,Im KM.Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.Oncogene2017;36:35-46 PMCID:PMC5140783

[47] Koster R,Timmer-Bosscha H.Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer.J Clin Invest2010;120:3594-605 PMCID:PMC2947220

[48] Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma.Nature2014;507:315-22 PMCID:PMC3962515

[49] Robertson AG, Kim J, Al-Ahmadie H, et al; TCGA Research Network. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540-56.e25.Cell2017;171:540-56.e25 PMCID:PMC5687509

[50] Samimi G,Katano K.Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.Clin Cancer Res2004;10:4661-9

[51] Li ZH,Chen JT,Qiu M.The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer (ESCC).J Cancer2016;7:2085-92 PMCID:PMC5118672

[52] Li YQ,Liu ZQ.Copper efflux transporters ATP7A and ATP7B: novel biomarkers for platinum drug resistance and targets for therapy.IUBMB Life2018;70:183-91

[53] Mangelinck A,Stefanovska B.MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma.Sci Rep2019;9:12301 PMCID:PMC6707240

[54] Krause W.Resistance to anti-tubulin agents: from vinca alkaloids to epothilones.Cancer Drug Resist2019;2:82-106 PMCID:PMC9019178

[55] Seremak JR,Bonigala S.Targeting chemoresistance in advanced bladder cancers with a novel adjuvant strategy.Mol Cancer Ther2024;23:1389-403. PMCID:PMC11607184

[56] Saiki Y,Horii A.Attempts to remodel the pathways of gemcitabine metabolism: recent approaches to overcoming tumours with acquired chemoresistance.Cancer Drug Resist2020;3:819-31 PMCID:PMC8992552